Stefanos Roumeliotis1,2, Vassilios Liakopoulos3, Athanasios Roumeliotis1, Aikaterini Stamou4, Stylianos Panagoutsos5, Graziella D'Arrigo2, Giovanni Tripepi2. 1. Division of Nephrology and Hypertension, First Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636, Thessaloniki, Greece. 2. Institute of Clinical Physiology (IFC-CNR), Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, 89127, Reggio Calabria, Italy. 3. Division of Nephrology and Hypertension, First Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636, Thessaloniki, Greece. liakopul@otenet.gr. 4. Department of Microbiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636, Thessaloniki, Greece. 5. Department of Nephrology, School of Medicine, Democritus University of Thrace, 68100, Alexandroupolis, Greece.
Abstract
PURPOSE: We aimed to assess whether high-density lipoprotein (HDL) cholesterol modifies the association between adiponectin and incident cardiovascular (CV) morbidity and mortality in Type 2 Diabetes Mellitus (T2DM) and vice versa. METHODS: At baseline, 106 T2DM participants with various degrees of renal function were enrolled and followed up over a period of 7 years with fatal/nonfatal CV events as outcome. RESULTS: During the follow-up, 49 participants experienced incident CV events (28 fatal, 21 nonfatal). On univariate Fine and Gray sub-hazard models, HDL cholesterol was a strong modifier of the association between adiponectin and CV outcomes both on crude (P = 0.011) and gender- and eGFR-adjusted models (P = 0.010). The protective effect for CV events portended by a fixed increase in adiponectin (1 μg/ml) was progressively higher across increasing values of HDL cholesterol. Moreover, plasma adiponectin also modified the protective effect of HDL on CV outcomes both in crude and multivariate analyses. We found a mutual effect modification between adiponectin and HDL as risk factors of CV events in participants with T2DM. CONCLUSION: Our results are coherent with the hypothesis that HDL cholesterol might play a pivotal role in the interpretation of the association between adiponectin and the risk of adverse CV outcomes in this population.
PURPOSE: We aimed to assess whether high-density lipoprotein (HDL) cholesterol modifies the association between adiponectin and incident cardiovascular (CV) morbidity and mortality in Type 2 Diabetes Mellitus (T2DM) and vice versa. METHODS: At baseline, 106 T2DM participants with various degrees of renal function were enrolled and followed up over a period of 7 years with fatal/nonfatal CV events as outcome. RESULTS: During the follow-up, 49 participants experienced incident CV events (28 fatal, 21 nonfatal). On univariate Fine and Gray sub-hazard models, HDL cholesterol was a strong modifier of the association between adiponectin and CV outcomes both on crude (P = 0.011) and gender- and eGFR-adjusted models (P = 0.010). The protective effect for CV events portended by a fixed increase in adiponectin (1 μg/ml) was progressively higher across increasing values of HDL cholesterol. Moreover, plasma adiponectin also modified the protective effect of HDL on CV outcomes both in crude and multivariate analyses. We found a mutual effect modification between adiponectin and HDL as risk factors of CV events in participants with T2DM. CONCLUSION: Our results are coherent with the hypothesis that HDL cholesterol might play a pivotal role in the interpretation of the association between adiponectin and the risk of adverse CV outcomes in this population.
Authors: Sophie Van Linthout; Anna Foryst-Ludwig; Frank Spillmann; Jun Peng; Yingmei Feng; Marco Meloni; Eline Van Craeyveld; Ulrich Kintscher; Heinz-Peter Schultheiss; Bart De Geest; Carsten Tschöpe Journal: Atherosclerosis Date: 2010-02-01 Impact factor: 5.162
Authors: Susana Coimbra; Flávio Reis; Sara Nunes; Sofia Viana; Maria João Valente; Susana Rocha; Cristina Catarino; Petronila Rocha-Pereira; Elsa Bronze-da-Rocha; Maria Sameiro-Faria; José Gerardo Oliveira; José Madureira; João Carlos Fernandes; Vasco Miranda; Luís Belo; Alice Santos-Silva Journal: Oxid Med Cell Longev Date: 2019-02-18 Impact factor: 6.543